Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Prostatic Neoplasms 3Pain, Postoperative 3Neoplasms 3Lung Neoplasms 3Breast Neoplasms 3Pancreatic Neoplasms 2Pain 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Anxiety Disorders 2Urinary Bladder Neoplasms 1Terminal Cancer 1Stomach Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sedation 1Rectal Neoplasms 1Postoperative Cognitive Complications 1Polyps 1Personal Satisfaction 1Patient Satisfaction 1Parasomnias 1Pancreatitis 1Pain, Intractable 1Opioid-Related Disorders 1Nausea 1Mouth Neoplasms 1Healthy 1Glioma 1

Interventions

Midazolam 2Meperidine 2Ketamine 1Etomidate 1Duodenoscopes 1Cholangiopancreatography, Endoscopic Retrograde 1Blood Culture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Choledocholithiasis × Midazolam × Clear all
NCT06111872 2025-03-25

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

National University of Malaysia

Phase 2 Completed
90 enrolled
Gastrointestinal

Cholangitis, Pancreatic Neoplasms, Choledochal Cyst, Choledocholithiasis

NCT02027311 2015-06-29

Etomidate vs. Midazolam for Sedation During ERCP

Cheju Halla General Hospital

Phase 4 Completed
63 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms, Pancreatitis, Cholangiocarcinoma, Choledocholithiasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡